Immunotherapy With a Stoma — What Changes and What Doesn’t

No — and for most people the more important answer is that they are not candidates anyway. A stoma neither qualifies you nor rules you out. In colorectal and lower GI cancer, checkpoint inhibitor immunotherapy is an evidence-based option only when the tumour is MSI-High, also reported as dMMR. Most patients are not in that group.

About 15 in 100 colorectal cancers across all stages are MSI-High. In advanced, metastatic disease the figure falls to roughly 4 to 5 in 100. These ranges follow NCCN and ESMO patient guidance current as of August 2026. If your report says MSS or pMMR, checkpoint inhibitor immunotherapy alone is not an evidence-based treatment for you, and chemotherapy, targeted therapy and clinical trials remain the established path.

The stoma plays no part in that decision. It is not a contraindication. It does not change the dose. It is not a reason a centre can decline immunotherapy. If you have been told the stoma is the obstacle, ask instead what your MMR or MSI result says, because that is the line that actually decides it. The full eligibility picture is set out in Immunotherapy for Colorectal Cancer: Only If You Are MSI-High.

What the stoma does change is everything that happens after treatment starts. The way immune side effects of the bowel are spotted was written for people who pass stool normally. That is the gap this page exists to close.

Eligibility is confirmed by an oncology team reading your own tissue report, not by this page. If you have not been told your MMR or MSI result, that is the first thing to ask for.

By comparing what enters the bag today with your own settled baseline. Immune colitis is inflammation of the bowel caused by immunotherapy. Without a stoma it is judged by counting extra stools a day. With a stoma there is no stool count, so output volume, consistency and emptying frequency become the measurement instead.

Two things make this harder than it sounds. A newly formed stoma takes weeks to settle, so “normal” is a moving target in the early period. And diet, dehydration, infection and previous radiotherapy can all shift output on their own. That is why your baseline is written down before the first cycle rather than reconstructed from memory afterwards.

Timing is a clue, not a rule. Immune colitis most often appears after the first few cycles, commonly within the first two to three months of starting, but it can begin at any point during treatment and even weeks after the last dose. There is no cycle number after which you can stop watching.

Telling the difference between an upset bowel and immune colitis is difficult with or without a stoma, and it is not something to settle at home. The general distinction is covered in stomach upset versus immune colitis.

A change from your own settled level, held for more than a day. Volume that roughly doubles, output that turns thin and watery when it was thicker, emptying far more often, and emptying overnight are the four that matter most. Blood or heavy mucus in the bag matters immediately, at any volume.

There is deliberately no home remedy on this page. Immune colitis is treated with prescribed medicines under supervision, and self-treatment delays the right treatment. Whoever you speak to, say in plain words that you are on immunotherapy — the reason that sentence matters so much is explained in why every doctor you meet needs to know you are on immunotherapy.

No. Same schedule, same dose, same day-care setting. Immunotherapy is given into a vein at a CION centre and you go home the same day. Your appliance, your pouching routine and your stoma nurse arrangements continue unchanged. Nothing about the infusion touches the stoma. What changes is monitoring, not treatment.

• Nothing is done to the stoma — the infusion goes into a vein through a cannula or a port. The stoma is not accessed, irrigated or altered for treatment.
• Bring supplies to the day-care unit — an infusion plus observation can run to a few hours. Carry a spare appliance, a change of clothes and disposal bags.
• Tell the day-care nurse you have a stoma — so a private space and a bin are arranged, and so any output change on the day is recorded rather than noticed and forgotten.
• Scans are coordinated, not in-house — response-assessment PET-CT is booked at partner imaging centres rather than performed at CION, so allow for travel and preparation time.
• Hydration is the habit to keep — a high-output stoma dehydrates quickly, and dehydration is also what makes a colitis episode dangerous. Ask your team what daily intake suits your stoma type.

Five things, and one of them exists only because you have a stoma. Eligibility is confirmed on tissue. Hepatitis B and C screening is completed as routine protocol. Baseline organ-function bloods are recorded. Your settled stoma output is written down. Your stoma nurse goes on the contact list. None of it is optional or unusual.

It can, and it is easily blamed on the appliance instead. Skin reactions are among the more common immune-related effects, and peristomal skin is skin like any other. Sore, red, broken skin around a stoma is also the everyday result of leakage or adhesive irritation, so the cause is not obvious by looking.

• Points towards an immune cause — a rash appearing elsewhere on the body at the same time, itching without any leak, or skin changing within weeks of starting treatment.
• Points towards appliance irritation — redness that follows the exact shape of the wafer or the barrier ring, or that started after changing brand or template size.
• Show it to your stoma nurse and tell oncology — both, not one. Say clearly that you are on immunotherapy, because the two teams will not otherwise share that detail on the same day.
• Do not start a steroid cream on your own — it changes how the appliance sticks, which causes more leakage, and it blurs the picture your team is trying to read.

The same principle runs through this whole page. A stoma does not create new immune side effects. It changes which of your senses you use to notice them, and it removes the one measurement the standard guidance assumes you have.

• Eligibility decided by a marker rather than by the organ is not unique to bowel cancer. Immunotherapy for Ovarian Cancer: Where the Evidence Stands shows the same logic where the eligible group is narrower still.
• In gynaecological cancers a different marker does the gatekeeping. HPV Status and Immunotherapy in Gynaecological Cancers explains how one test result changes the answer.
• Stoma output is one effect that gets missed because it does not look like a side effect. Menstrual Changes and Early Menopause on Immunotherapy is another of the same kind.
• Still working out whether immunotherapy applies to you at all? Start with the biomarker question in Immunotherapy for Colorectal Cancer: Only If You Are MSI-High.
• For how immunotherapy is delivered, monitored and paid for at CION, including day-care scheduling and scheme cover, see Immunotherapy at CION Cancer Clinics.

Not sure what your report says, or what your own baseline should be? Book a free consultation and a medical oncologist will go through both with you.